TrialJCO precision oncology2022

Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.

Frank A Sinicrope et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.